TY - JOUR AU - Farooqi, Javed Iqbal AU - Alam, Altaf AU - Abbas, Zaigham AU - Naqvi, Altaf Baqir AU - Zuberi, Bader Faiyaz AU - Nawaz, Arif Amir AU - Khan, Anwaar A AU - Hashmi, Zahid Yaseen AU - Chaudhry, Asad Ali AU - Azam, Zahid AU - Salih, Muhammed AU - Ali, Bushra AU - Siddiq, Masood AU - Kamani, Lubna AU - Ali, Zeeshan AU - Haider, Aftab AU - Majid, Shahid PY - 2016/02/06 Y2 - 2024/03/28 TI - HEP-NET OPINION ABOUT THE MANAGEMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN PAKISTAN IN THE ERA OF AVAILABLE DIRECT ACTING ANTIVIRALS JF - Journal of Postgraduate Medical Institute JA - J Postgrad Med Inst VL - 30 IS - 1 SE - Special Article DO - UR - https://www.jpmi.org.pk/index.php/jpmi/article/view/1889 SP - AB - <p>In Pakistan, we have 4.9% prevalence of HCV in general population, with 79% genotype 3. Recently Sofosbuvir has been made available at compassionate price in Pakistan. Management of chronic hepatitis C includes counseling of HCV patients, their proper assessment to select those who need antiviral therapy, initiation of appropriate antiviral agents &amp; duration of therapy, along-with careful monitoring for safety and efficacy. Hepatic status as well as pre-vious history of HCV therapy needs to be taken in the consideration before starting antiviral therapy. Other factors include co-morbid conditions like obesity, DM, NASH, etc. Treatment of special populations like liver transplant pa-tients, patients with HBV co-infection, chronic kidney disease and hemoglobinopathies need special considerations when initiating HCV therapy.</p> ER -